BioNTech's shares dip after posting lukewarm revenue guidance

Ayisha Sharma

News Reporter

BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s shares to slide about 2% on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech's shares dip after posting lukewarm revenue guidance

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New Flagship startup aims to trailblaze ‘AI science factories’

Beam shares promising first clinical data on gene editing treatment for a lung and liver disease

Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer

Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

Obesity drug development—still room to grow

BioN­Tech's shares dip af­ter post­ing luke­warm rev­enue guid­ance

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

BioNTech's shares dip after posting lukewarm revenue guidance